Obesity is a major risk factor for cardiovascular disease and diabetes. Weight loss is an important therapeutic goal for overweight and obese patients to reduce their risk of developing cardiovascular disease and diabetes. Liquid meal replacements (LMRs) are simple tools that may aid in weight loss and may improve weight-related risk cardiometabolic risk factors. There is a need to synthesize the evidence on LMRs and cardiometabolic risk to inform clinical practice guidelines. The authors propose to conduct a series of systematic review and meta-analysis of randomized controlled trials to evaluate the effect of LMRs on 4 areas of cardiometabolic risk: markers of adipsoity, glycemic control, established lipid targets, and blood pressure.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Markers of adiposity - body weight
Timeframe: Up to 20 years
Markers of adiposity - Body Mass Index
Timeframe: Up to 20 years
Markers of adiposity - body fat
Timeframe: Up to 20 years
Markers of adiposity - waist circumference
Timeframe: Up to 20 years
Glycemic control - HbA1c
Timeframe: Up to 20 years
Glycemic control - fasting glucose
Timeframe: Up to 20 years
Glycemic control - fasting insulin
Timeframe: Up to 20 years
Established therapeutic lipid targets - LDL-cholesterol
Timeframe: Up to 20 years
Established therapeutic lipid targets - apolipoprotein B
Timeframe: Up to 20 years
Established therapeutic lipid targets - non-HDL-cholesterol
Timeframe: Up to 20 years
Established therapeutic lipid targets - HDL-cholesterol
Timeframe: Up to 20 years
Established therapeutic lipid targets - triglycerides
Timeframe: Up to 20 years
Blood pressure - systolic blood pressure
Timeframe: Up to 20 years
Blood pressure - diastolic blood pressure
Timeframe: Up to 20 years